SEC Form SC 13G filed by Miromatrix Medical Inc.

$MIRO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $MIRO alert in real time by email
SC 13G 1 miromatrix_13g.htm SC 13G
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13G
 
Under the Securities Exchange Act of 1934
 
(Amendment No.    )*
 
Miromatrix Medical Inc.
(Name of Issuer)
 
Common Stock, par value $0.00001 per share
(Title of Class of Securities)
 
60471P108
(CUSIP Number)
 
February 11, 2022
(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
o Rule 13d-1(b)
x Rule 13d-1(c)
o Rule 13d-1(d)
   

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).  

 
 
CUSIP No. 60471P108 13G Page 2 of 8

 

             
1.

Names Of Reporting Persons

I.R.S. Identification No. Of Above Persons (Entities Only)

 

GAGNON SECURITIES LLC

 

 
       
2. check the appropriate box if a group (a) o
(b) x

3. sec use only    
       
4.

citizenship or place of organization

 

DELAWARE LIMITED LIABILITY COMPANY

 

   
number of
shares
beneficially
owned by
each
reporting
person with:
5. sole voting power     0
6. shared voting power     650,444
7. sole dispositive power     0
8. shared dispositive power     684,984
9. aggregate amount beneficially owned by each reporting person   684,984
10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o
11. percent of class represented by amount in row (9)  

3.4%

12. type of reporting person (See Instructions)     IA, BD

 

 
 
 
CUSIP No. 60471P108 13G Page 3 of 8

 

             
1.

Names Of Reporting Persons

 

GAGNON ADVISORS, LLC

 

 
       
2. check the appropriate box if a group (a) o
(b) x

3. sec use only    
       
4.

citizenship or place of organization

 

DELAWARE LIMITED LIABILITY COMPANY

 

   
number of
shares
beneficially
owned by
each
reporting
person with:
5. sole voting power     0
6. shared voting power     229,802
7. sole dispositive power     0
8. shared dispositive power    

229,802

9. aggregate amount beneficially owned by each reporting person  

229,802

10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o
11. percent of class represented by amount in row (9)  

1.1%

12. type of reporting person (See Instructions)     IA

 

 
 
 
CUSIP No. 60471P108 13G Page 4 of 8

 

             
1.

Names Of Reporting Persons

 

NEIL GAGNON

 

 
       
2. check the appropriate box if a group (a) o
(b) x

3. sec use only    
       
4.

citizenship or place of organization

 

USA

 

   
number of
shares
beneficially
owned by
each
reporting
person with:
5. sole voting power    

65,711

6. shared voting power    

915,651

7. sole dispositive power    

65,711

8. shared dispositive power    

952,753

9. aggregate amount beneficially owned by each reporting person  

1,018,464

10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o
11. percent of class represented by amount in row (9)  

5.0%

12. type of reporting person (See Instructions)     IN

 

 
 
 
CUSIP No. 60471P108 13G Page 5 of 8
Item 1.  

 

(a) Name of Issuer: Micromatrix Medical Inc.
     
(b) Address of Issuer’s Principal

10399 West 70th Street

  Executive Offices:

Eden Prairie, MN 55344

 

Item 2.

(a) Name of Person Filing:

Neil Gagnon has sole voting and dispositive power over 65,711 shares of the Issuer’s common stock, par value $0.00001 per share (the “Common Stock”). In addition, Mr. Gagnon has shared voting power over 915,651 shares of the Issuer’s Common Stock and shared dispositive power over 952,753 shares of Common Stock.

 

Mr. Gagnon is the managing member and principal owner of Gagnon Securities LLC (“GS”), an investment adviser registered with the U.S. Securities and Exchange Commission (“SEC”) under the Investment Advisers Act of 1940, as amended (the “Advisers Act”), and a registered broker-dealer, in its role as investment manager to several customer accounts, foundations, partnerships and trusts (collectively, the “Accounts”) to which it furnishes investment advice. GS and Mr. Gagnon may be deemed to share voting power with respect to 650,444 shares of Common Stock held in the Accounts and dispositive power with respect to 684,984 shares of the Issuer’s Common Stock held in the Accounts. GS and Mr. Gagnon expressly disclaim beneficial ownership of all securities held in the Accounts.

 

Mr. Gagnon is also the Chief Executive Officer of Gagnon Advisors, LLC (“Gagnon Advisors”), an investment adviser registered with the SEC under the Advisers Act. Mr. Gagnon and Gagnon Advisors, in its role as investment manager to Gagnon Investment Associates, LLC (“GIA”), a private investment fund, may be deemed to share voting and dispositive power with respect to the 229,802 shares of the Issuer’s Common Stock held by GIA. Gagnon Advisors and Mr. Gagnon expressly disclaim beneficial ownership of all securities held by GIA.

 

(b) Address of Principal Business Office 1370 Ave. of the Americas, 24th Floor
  or, if none, Residence: New York, NY 10019

 

(c) Citizenship:

Gagnon Securities LLC

Delaware limited liability company

   

Gagnon Advisors, LLC

Delaware limited liability company

   

Neil Gagnon

USA

     
(d) Title of Class of Securities:

Common Stock, $0.00001 per share

     
(e) CUSIP Number: 60471P108

 

 
 
 
CUSIP No. 60471P108 13G Page 6 of 8
   
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

 

(a)  o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
     
(b)  o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
     
(c)  o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
     
(d)  o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
     
(e)  o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
(f)  o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
(g)  o A parent holding company or control person in accordance with § 13d-1(b)(1)(ii)(G);
     
(h)  o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
(i)  o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15U.S.C. 80a-3);
     
(j)  o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
(k)  o Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

 

 
 
 
CUSIP No. 60471P108 13G Page 7 of 8
Item 4. Ownership.

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

  (a) Amount beneficially owned:

Gagnon Securities LLC

684,984

     

Gagnon Advisors, LLC

229,802

     

Neil Gagnon

1,018,464

       
  (b) Percent of class:

Gagnon Securities LLC

3.4%

     

Gagnon Advisors, LLC

1.1%

     

Neil Gagnon

5.0%

       
     

Calculation of percentage of beneficial ownership is based on 20,254,645 shares of Common Stock outstanding as of November 11, 2021 as disclosed in the issuer’s quarterly report on Form 10-Q dated November 15, 2021.

       
  (c) Number of shares as to which the person has:

 

  (i) Sole power to vote or to direct the vote:

Gagnon Securities LLC

0

     

Gagnon Advisors, LLC

0
     

Neil Gagnon

65,711

       
  (ii) Shared power to vote or to direct the vote:

Gagnon Securities LLC

650,444

     

Gagnon Advisors, LLC

229,802

     

Neil Gagnon

915,651

       
  (iii) Sole power to dispose or to direct the disposition of:

Gagnon Securities LLC

0
     

Gagnon Advisors, LLC

0
     

Neil Gagnon

65,711

       
  (iv) Shared power to dispose or to direct the disposition of:

Gagnon Securities LLC

684,984

     

Gagnon Advisors, LLC

229,802

     

Neil Gagnon

952,753

Item 5. Ownership of Five Percent or Less of a Class.
   

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

The Accounts described above in Item 2 have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, securities held in their respective accounts. To the knowledge of the Reporting Persons the interest in any such account does not exceed 5% of the class of securities. Except to the extent described herein, the Reporting Person disclaims beneficial ownership of all such securities.

 

Items 7 – 9. Not Applicable.

 

 
 
 
CUSIP No. 60471P108 13G Page 8 of 8
   
Item 10. Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Section 230.14a-11.

 

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 16, 2022

   
  NEIL GAGNON
   
 

/s/ Neil Gagnon

   
 

GAGNON SECURITIES LLC

   
 

/s/ Neil Gagnon

  Name:  Neil Gagnon 
 

Title:    Managing Member

   
 

GAGNON ADVISORS, LLC

   
 

/s/ Neil Gagnon

  Name:  Neil Gagnon 
 

Title:    Chief Executive Officer

   
 
 
Get the next $MIRO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MIRO

DatePrice TargetRatingAnalyst
7/19/2021$22.00Buy
Craig Hallum
More analyst ratings

$MIRO
Press Releases

Fastest customizable press release news feed in the world

See more
  • United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger

    United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today that United Therapeutics, through its wholly owned subsidiary Morpheus Subsidiary Inc. ("Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix's development-stage, fully-implantable manufactured kidney product known as mirokidney™ by December 31, 2025. The tender offer expired at one minute after 11:59 p.m., New York City time, on Decem

    $MIRO
    $UTHR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • United Therapeutics and Miromatrix Medical Announce Successful Tender Offer

    United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced today the results of the previously announced tender offer by Morpheus Subsidiary Inc. ("Merger Sub"), a wholly owned subsidiary of United Therapeutics, to acquire all outstanding shares of Miromatrix for a purchase price of $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix's development-stage, fully-implantable manufactured kidney product known as mirokidney™ by December 31, 2025. The tender offer expired at one minute after 11:59 p.m., New York City time, on December 11, 2023. Contine

    $MIRO
    $UTHR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Miromatrix Reports Third Quarter 2023 Results

    EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO) (the "Company"), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported third quarter 2023 financial results. Due to the Company's pending proposed transaction with United Therapeutics Corporation (NASDAQ:UTHR) ("United Therapeutics"), the Company's management has suspended guidance for 2023 and will not hold a conference call to discuss third quarter 2023 results. Third Quarter 2023 Financial Results Unrestricted cash and investments totaled $16.1 million as of September 30, 2023, compared to

    $MIRO
    $UTHR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

$MIRO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MIRO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MIRO
SEC Filings

See more

$MIRO
Leadership Updates

Live Leadership Updates

See more
  • ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial Officer

    DENVER, Jan. 9, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2022 Preliminary Results and Other Data (Unaudited)Received nine new orders for MRIdian systems totaling approximately $56 million, compared to seven new orders totaling approximately $41 million in the fourth quarter of 2021. A total of 32 orders were received for the twelve months ended December 31, 2022, compared to 28 orders for the twelve months ended December 31, 2021. Total backlog i

    $AXGN
    $MIRO
    $VRAY
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Miromatrix Appoints Jack Lake, M.D., as Medical Director

    EDEN PRAIRIE, Minn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced today that it has appointed Jack Lake, M.D. as the Company's new Medical Director. Dr. Lake is a Professor of Surgery and Medicine and the Chief of Hepatology in the Department of Medicine at the University of Minnesota. He is also the Executive Medical Director for Solid Organ Transplantation at the University of Minnesota Medical Center. Dr. Lake will serve as Miromatrix's Medical Director while remaining in his current roles at the Universit

    $MIRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Miromatrix Names Jim Douglas as New Chief Financial Officer

    EDEN PRAIRIE, Minn., March 01, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced the appointment of Jim Douglas as the Company's new Chief Financial Officer (CFO) effective March 1, 2022. As CFO, Jim will lead Miromatrix's finance organization and oversee all financial activities of the corporation. Mr. Douglas will succeed Brian Niebur, who will continue to serve Miromatrix as the Vice President of Finance. "On behalf of everyone at Miromatrix and our Board of Directors, I want to thank Brian for his many contributions duri

    $MIRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$MIRO
Financials

Live finance-specific insights

See more
  • Miromatrix Reports Third Quarter 2023 Results

    EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO) (the "Company"), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported third quarter 2023 financial results. Due to the Company's pending proposed transaction with United Therapeutics Corporation (NASDAQ:UTHR) ("United Therapeutics"), the Company's management has suspended guidance for 2023 and will not hold a conference call to discuss third quarter 2023 results. Third Quarter 2023 Financial Results Unrestricted cash and investments totaled $16.1 million as of September 30, 2023, compared to

    $MIRO
    $UTHR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Miromatrix Reports Second Quarter 2023 Results and Provides Corporate Update

    EDEN PRAIRIE, Minn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported second quarter 2023 financial results and provided a corporate update. "Miromatrix remains on pace to submit a response to the FDA's clinical hold letter relating to our miroliverELAPtm IND application in the second half of 2023," said Jeff Ross, Ph.D., Miromatrix CEO. "We continue to progress towards our goal of gaining authorization from the FDA to initiate a Phase 1 clinical trial to treat patients suffering from acute liver failure and

    $MIRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Miromatrix to Report Second Quarter 2023 Financial Results

    EDEN PRAIRIE, Minn., July 25, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the second quarter 2023 after market close on Monday, August 14, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time. Individuals interested in listening to the conference call may do so by dialing 866-652-5200 for domestic callers or 412-317-6060 for international callers. Please reference Conference ID: 10181369. To l

    $MIRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$MIRO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more